Neuroene Therapeutics
Private Company
Funding information not available
Overview
Neuroene Therapeutics is advancing a proprietary platform of orally bioavailable Vitamin K analogs designed to improve mitochondrial health and energetics in the brain. The company's lead candidate has demonstrated broad-spectrum antiseizure activity in animal models of pharmacoresistant epilepsy and Parkinson's, positioning it as a potential chronic therapeutic and fast-acting rescue agent. Recent milestones include an NIH SBIR grant and selection as a finalist for high-profile biotech pitching events, validating its approach to a significant unmet medical need.
Technology Platform
Proprietary, orally bioavailable Vitamin K (VK) analog small molecules designed to target mitochondrial health and energetics in the brain to treat neurological dysfunction.
Opportunities
Risk Factors
Competitive Landscape
The neurology space is highly competitive with many large pharma and biotech firms. Neuroene's differentiation lies in its specific focus on mitochondrial health via VK analogs, a niche approach. Competitors include companies developing other neuroprotective agents, next-generation anti-seizure medications, and disease-modifying therapies for Parkinson's.